Global Neurodegenerative Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
According to our (Global Info Research) latest study, the global Neurodegenerative Drugs market size was valued at USD 118360 million in 2023 and is forecast to a readjusted size of USD 174250 million by 2030 with a CAGR of 5.7% during review period.
Neurodegenerative drugs are medications used to manage and alleviate symptoms associated with neurodegenerative diseases. They may target various aspects of disease progression, such as cognitive function, motor symptoms, and inflammation.
The market for neurodegenerative drugs is driven by the growing burden of neurodegenerative diseases and the need for effective and disease-modifying treatments. The market's growth is also influenced by ongoing research in neuroscience and the development of novel drug candidates targeting specific neurodegenerative pathways.
The Global Info Research report includes an overview of the development of the Neurodegenerative Drugs industry chain, the market status of Parkinson’s Disease (NMDA, SSRIs), Huntington Disease (NMDA, SSRIs), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Neurodegenerative Drugs.
Regionally, the report analyzes the Neurodegenerative Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Neurodegenerative Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Neurodegenerative Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Neurodegenerative Drugs industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (MT), revenue generated, and market share of different by Type (e.g., NMDA, SSRIs).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Neurodegenerative Drugs market.
Regional Analysis: The report involves examining the Neurodegenerative Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Neurodegenerative Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Neurodegenerative Drugs:
Company Analysis: Report covers individual Neurodegenerative Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Neurodegenerative Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Parkinson’s Disease, Huntington Disease).
Technology Analysis: Report covers specific technologies relevant to Neurodegenerative Drugs. It assesses the current state, advancements, and potential future developments in Neurodegenerative Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Neurodegenerative Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Neurodegenerative Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe Neurodegenerative Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Neurodegenerative Drugs, with price, sales, revenue and global market share of Neurodegenerative Drugs from 2019 to 2024.
Chapter 3, the Neurodegenerative Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neurodegenerative Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Neurodegenerative Drugs market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Neurodegenerative Drugs.
Chapter 14 and 15, to describe Neurodegenerative Drugs sales channel, distributors, customers, research findings and conclusion.
Neurodegenerative drugs are medications used to manage and alleviate symptoms associated with neurodegenerative diseases. They may target various aspects of disease progression, such as cognitive function, motor symptoms, and inflammation.
The market for neurodegenerative drugs is driven by the growing burden of neurodegenerative diseases and the need for effective and disease-modifying treatments. The market's growth is also influenced by ongoing research in neuroscience and the development of novel drug candidates targeting specific neurodegenerative pathways.
The Global Info Research report includes an overview of the development of the Neurodegenerative Drugs industry chain, the market status of Parkinson’s Disease (NMDA, SSRIs), Huntington Disease (NMDA, SSRIs), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Neurodegenerative Drugs.
Regionally, the report analyzes the Neurodegenerative Drugs markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Neurodegenerative Drugs market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Neurodegenerative Drugs market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Neurodegenerative Drugs industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (MT), revenue generated, and market share of different by Type (e.g., NMDA, SSRIs).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Neurodegenerative Drugs market.
Regional Analysis: The report involves examining the Neurodegenerative Drugs market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Neurodegenerative Drugs market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Neurodegenerative Drugs:
Company Analysis: Report covers individual Neurodegenerative Drugs manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Neurodegenerative Drugs This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Parkinson’s Disease, Huntington Disease).
Technology Analysis: Report covers specific technologies relevant to Neurodegenerative Drugs. It assesses the current state, advancements, and potential future developments in Neurodegenerative Drugs areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Neurodegenerative Drugs market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Neurodegenerative Drugs market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- NMDA
- SSRIs
- Dopamine Inhibitors
- Parkinson’s Disease
- Huntington Disease
- Amyotrophic Lateral Sclerosis
- Alzheimer’s Disease
- Novartis
- Pfizer
- Merck Serono
- Biogen Idec
- TEVA
- UCB
- Boehringer Ingelheim
- Sanofi
- GlaxoSmithKline
- Livzon Pharmaceutical
- Haisco Pharmaceutical
- Jingxin Pharmaceutical
- Dongcheng Biochemicals
- Hisun Pharmaceutical
- Luye Pharma
- Ark Pharmaceutical
- Kanghong Pharmaceutical
- Huahai Pharmaceutical
- BORA PHARMACEUTICALS
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe Neurodegenerative Drugs product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Neurodegenerative Drugs, with price, sales, revenue and global market share of Neurodegenerative Drugs from 2019 to 2024.
Chapter 3, the Neurodegenerative Drugs competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Neurodegenerative Drugs breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2023.and Neurodegenerative Drugs market forecast, by regions, type and application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Neurodegenerative Drugs.
Chapter 14 and 15, to describe Neurodegenerative Drugs sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Neurodegenerative Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Neurodegenerative Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 NMDA
1.3.3 SSRIs
1.3.4 Dopamine Inhibitors
1.4 Market Analysis by Application
1.4.1 Overview: Global Neurodegenerative Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Parkinson’s Disease
1.4.3 Huntington Disease
1.4.4 Amyotrophic Lateral Sclerosis
1.4.5 Alzheimer’s Disease
1.5 Global Neurodegenerative Drugs Market Size & Forecast
1.5.1 Global Neurodegenerative Drugs Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Neurodegenerative Drugs Sales Quantity (2019-2030)
1.5.3 Global Neurodegenerative Drugs Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Neurodegenerative Drugs Product and Services
2.1.4 Novartis Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Novartis Recent Developments/Updates
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Neurodegenerative Drugs Product and Services
2.2.4 Pfizer Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Pfizer Recent Developments/Updates
2.3 Merck Serono
2.3.1 Merck Serono Details
2.3.2 Merck Serono Major Business
2.3.3 Merck Serono Neurodegenerative Drugs Product and Services
2.3.4 Merck Serono Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Merck Serono Recent Developments/Updates
2.4 Biogen Idec
2.4.1 Biogen Idec Details
2.4.2 Biogen Idec Major Business
2.4.3 Biogen Idec Neurodegenerative Drugs Product and Services
2.4.4 Biogen Idec Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Biogen Idec Recent Developments/Updates
2.5 TEVA
2.5.1 TEVA Details
2.5.2 TEVA Major Business
2.5.3 TEVA Neurodegenerative Drugs Product and Services
2.5.4 TEVA Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 TEVA Recent Developments/Updates
2.6 UCB
2.6.1 UCB Details
2.6.2 UCB Major Business
2.6.3 UCB Neurodegenerative Drugs Product and Services
2.6.4 UCB Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 UCB Recent Developments/Updates
2.7 Boehringer Ingelheim
2.7.1 Boehringer Ingelheim Details
2.7.2 Boehringer Ingelheim Major Business
2.7.3 Boehringer Ingelheim Neurodegenerative Drugs Product and Services
2.7.4 Boehringer Ingelheim Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Boehringer Ingelheim Recent Developments/Updates
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Neurodegenerative Drugs Product and Services
2.8.4 Sanofi Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Sanofi Recent Developments/Updates
2.9 GlaxoSmithKline
2.9.1 GlaxoSmithKline Details
2.9.2 GlaxoSmithKline Major Business
2.9.3 GlaxoSmithKline Neurodegenerative Drugs Product and Services
2.9.4 GlaxoSmithKline Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 GlaxoSmithKline Recent Developments/Updates
2.10 Livzon Pharmaceutical
2.10.1 Livzon Pharmaceutical Details
2.10.2 Livzon Pharmaceutical Major Business
2.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Product and Services
2.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Livzon Pharmaceutical Recent Developments/Updates
2.11 Haisco Pharmaceutical
2.11.1 Haisco Pharmaceutical Details
2.11.2 Haisco Pharmaceutical Major Business
2.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Product and Services
2.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Haisco Pharmaceutical Recent Developments/Updates
2.12 Jingxin Pharmaceutical
2.12.1 Jingxin Pharmaceutical Details
2.12.2 Jingxin Pharmaceutical Major Business
2.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Product and Services
2.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Jingxin Pharmaceutical Recent Developments/Updates
2.13 Dongcheng Biochemicals
2.13.1 Dongcheng Biochemicals Details
2.13.2 Dongcheng Biochemicals Major Business
2.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Product and Services
2.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Dongcheng Biochemicals Recent Developments/Updates
2.14 Hisun Pharmaceutical
2.14.1 Hisun Pharmaceutical Details
2.14.2 Hisun Pharmaceutical Major Business
2.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Product and Services
2.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.14.5 Hisun Pharmaceutical Recent Developments/Updates
2.15 Luye Pharma
2.15.1 Luye Pharma Details
2.15.2 Luye Pharma Major Business
2.15.3 Luye Pharma Neurodegenerative Drugs Product and Services
2.15.4 Luye Pharma Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.15.5 Luye Pharma Recent Developments/Updates
2.16 Ark Pharmaceutical
2.16.1 Ark Pharmaceutical Details
2.16.2 Ark Pharmaceutical Major Business
2.16.3 Ark Pharmaceutical Neurodegenerative Drugs Product and Services
2.16.4 Ark Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.16.5 Ark Pharmaceutical Recent Developments/Updates
2.17 Kanghong Pharmaceutical
2.17.1 Kanghong Pharmaceutical Details
2.17.2 Kanghong Pharmaceutical Major Business
2.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Product and Services
2.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.17.5 Kanghong Pharmaceutical Recent Developments/Updates
2.18 Huahai Pharmaceutical
2.18.1 Huahai Pharmaceutical Details
2.18.2 Huahai Pharmaceutical Major Business
2.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Product and Services
2.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.18.5 Huahai Pharmaceutical Recent Developments/Updates
2.19 BORA PHARMACEUTICALS
2.19.1 BORA PHARMACEUTICALS Details
2.19.2 BORA PHARMACEUTICALS Major Business
2.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Product and Services
2.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.19.5 BORA PHARMACEUTICALS Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: NEURODEGENERATIVE DRUGS BY MANUFACTURER
3.1 Global Neurodegenerative Drugs Sales Quantity by Manufacturer (2019-2024)
3.2 Global Neurodegenerative Drugs Revenue by Manufacturer (2019-2024)
3.3 Global Neurodegenerative Drugs Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Neurodegenerative Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Neurodegenerative Drugs Manufacturer Market Share in 2023
3.4.2 Top 6 Neurodegenerative Drugs Manufacturer Market Share in 2023
3.5 Neurodegenerative Drugs Market: Overall Company Footprint Analysis
3.5.1 Neurodegenerative Drugs Market: Region Footprint
3.5.2 Neurodegenerative Drugs Market: Company Product Type Footprint
3.5.3 Neurodegenerative Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Neurodegenerative Drugs Market Size by Region
4.1.1 Global Neurodegenerative Drugs Sales Quantity by Region (2019-2030)
4.1.2 Global Neurodegenerative Drugs Consumption Value by Region (2019-2030)
4.1.3 Global Neurodegenerative Drugs Average Price by Region (2019-2030)
4.2 North America Neurodegenerative Drugs Consumption Value (2019-2030)
4.3 Europe Neurodegenerative Drugs Consumption Value (2019-2030)
4.4 Asia-Pacific Neurodegenerative Drugs Consumption Value (2019-2030)
4.5 South America Neurodegenerative Drugs Consumption Value (2019-2030)
4.6 Middle East and Africa Neurodegenerative Drugs Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
5.2 Global Neurodegenerative Drugs Consumption Value by Type (2019-2030)
5.3 Global Neurodegenerative Drugs Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
6.2 Global Neurodegenerative Drugs Consumption Value by Application (2019-2030)
6.3 Global Neurodegenerative Drugs Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
7.2 North America Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
7.3 North America Neurodegenerative Drugs Market Size by Country
7.3.1 North America Neurodegenerative Drugs Sales Quantity by Country (2019-2030)
7.3.2 North America Neurodegenerative Drugs Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
8.2 Europe Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
8.3 Europe Neurodegenerative Drugs Market Size by Country
8.3.1 Europe Neurodegenerative Drugs Sales Quantity by Country (2019-2030)
8.3.2 Europe Neurodegenerative Drugs Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Neurodegenerative Drugs Market Size by Region
9.3.1 Asia-Pacific Neurodegenerative Drugs Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Neurodegenerative Drugs Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
10.2 South America Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
10.3 South America Neurodegenerative Drugs Market Size by Country
10.3.1 South America Neurodegenerative Drugs Sales Quantity by Country (2019-2030)
10.3.2 South America Neurodegenerative Drugs Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Neurodegenerative Drugs Market Size by Country
11.3.1 Middle East & Africa Neurodegenerative Drugs Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Neurodegenerative Drugs Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Neurodegenerative Drugs Market Drivers
12.2 Neurodegenerative Drugs Market Restraints
12.3 Neurodegenerative Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Neurodegenerative Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Neurodegenerative Drugs
13.3 Neurodegenerative Drugs Production Process
13.4 Neurodegenerative Drugs Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Neurodegenerative Drugs Typical Distributors
14.3 Neurodegenerative Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of Neurodegenerative Drugs
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global Neurodegenerative Drugs Consumption Value by Type: 2019 Versus 2023 Versus 2030
1.3.2 NMDA
1.3.3 SSRIs
1.3.4 Dopamine Inhibitors
1.4 Market Analysis by Application
1.4.1 Overview: Global Neurodegenerative Drugs Consumption Value by Application: 2019 Versus 2023 Versus 2030
1.4.2 Parkinson’s Disease
1.4.3 Huntington Disease
1.4.4 Amyotrophic Lateral Sclerosis
1.4.5 Alzheimer’s Disease
1.5 Global Neurodegenerative Drugs Market Size & Forecast
1.5.1 Global Neurodegenerative Drugs Consumption Value (2019 & 2023 & 2030)
1.5.2 Global Neurodegenerative Drugs Sales Quantity (2019-2030)
1.5.3 Global Neurodegenerative Drugs Average Price (2019-2030)
2 MANUFACTURERS PROFILES
2.1 Novartis
2.1.1 Novartis Details
2.1.2 Novartis Major Business
2.1.3 Novartis Neurodegenerative Drugs Product and Services
2.1.4 Novartis Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.1.5 Novartis Recent Developments/Updates
2.2 Pfizer
2.2.1 Pfizer Details
2.2.2 Pfizer Major Business
2.2.3 Pfizer Neurodegenerative Drugs Product and Services
2.2.4 Pfizer Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.2.5 Pfizer Recent Developments/Updates
2.3 Merck Serono
2.3.1 Merck Serono Details
2.3.2 Merck Serono Major Business
2.3.3 Merck Serono Neurodegenerative Drugs Product and Services
2.3.4 Merck Serono Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.3.5 Merck Serono Recent Developments/Updates
2.4 Biogen Idec
2.4.1 Biogen Idec Details
2.4.2 Biogen Idec Major Business
2.4.3 Biogen Idec Neurodegenerative Drugs Product and Services
2.4.4 Biogen Idec Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.4.5 Biogen Idec Recent Developments/Updates
2.5 TEVA
2.5.1 TEVA Details
2.5.2 TEVA Major Business
2.5.3 TEVA Neurodegenerative Drugs Product and Services
2.5.4 TEVA Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.5.5 TEVA Recent Developments/Updates
2.6 UCB
2.6.1 UCB Details
2.6.2 UCB Major Business
2.6.3 UCB Neurodegenerative Drugs Product and Services
2.6.4 UCB Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.6.5 UCB Recent Developments/Updates
2.7 Boehringer Ingelheim
2.7.1 Boehringer Ingelheim Details
2.7.2 Boehringer Ingelheim Major Business
2.7.3 Boehringer Ingelheim Neurodegenerative Drugs Product and Services
2.7.4 Boehringer Ingelheim Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.7.5 Boehringer Ingelheim Recent Developments/Updates
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Neurodegenerative Drugs Product and Services
2.8.4 Sanofi Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.8.5 Sanofi Recent Developments/Updates
2.9 GlaxoSmithKline
2.9.1 GlaxoSmithKline Details
2.9.2 GlaxoSmithKline Major Business
2.9.3 GlaxoSmithKline Neurodegenerative Drugs Product and Services
2.9.4 GlaxoSmithKline Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.9.5 GlaxoSmithKline Recent Developments/Updates
2.10 Livzon Pharmaceutical
2.10.1 Livzon Pharmaceutical Details
2.10.2 Livzon Pharmaceutical Major Business
2.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Product and Services
2.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.10.5 Livzon Pharmaceutical Recent Developments/Updates
2.11 Haisco Pharmaceutical
2.11.1 Haisco Pharmaceutical Details
2.11.2 Haisco Pharmaceutical Major Business
2.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Product and Services
2.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.11.5 Haisco Pharmaceutical Recent Developments/Updates
2.12 Jingxin Pharmaceutical
2.12.1 Jingxin Pharmaceutical Details
2.12.2 Jingxin Pharmaceutical Major Business
2.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Product and Services
2.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.12.5 Jingxin Pharmaceutical Recent Developments/Updates
2.13 Dongcheng Biochemicals
2.13.1 Dongcheng Biochemicals Details
2.13.2 Dongcheng Biochemicals Major Business
2.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Product and Services
2.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.13.5 Dongcheng Biochemicals Recent Developments/Updates
2.14 Hisun Pharmaceutical
2.14.1 Hisun Pharmaceutical Details
2.14.2 Hisun Pharmaceutical Major Business
2.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Product and Services
2.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.14.5 Hisun Pharmaceutical Recent Developments/Updates
2.15 Luye Pharma
2.15.1 Luye Pharma Details
2.15.2 Luye Pharma Major Business
2.15.3 Luye Pharma Neurodegenerative Drugs Product and Services
2.15.4 Luye Pharma Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.15.5 Luye Pharma Recent Developments/Updates
2.16 Ark Pharmaceutical
2.16.1 Ark Pharmaceutical Details
2.16.2 Ark Pharmaceutical Major Business
2.16.3 Ark Pharmaceutical Neurodegenerative Drugs Product and Services
2.16.4 Ark Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.16.5 Ark Pharmaceutical Recent Developments/Updates
2.17 Kanghong Pharmaceutical
2.17.1 Kanghong Pharmaceutical Details
2.17.2 Kanghong Pharmaceutical Major Business
2.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Product and Services
2.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.17.5 Kanghong Pharmaceutical Recent Developments/Updates
2.18 Huahai Pharmaceutical
2.18.1 Huahai Pharmaceutical Details
2.18.2 Huahai Pharmaceutical Major Business
2.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Product and Services
2.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.18.5 Huahai Pharmaceutical Recent Developments/Updates
2.19 BORA PHARMACEUTICALS
2.19.1 BORA PHARMACEUTICALS Details
2.19.2 BORA PHARMACEUTICALS Major Business
2.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Product and Services
2.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
2.19.5 BORA PHARMACEUTICALS Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: NEURODEGENERATIVE DRUGS BY MANUFACTURER
3.1 Global Neurodegenerative Drugs Sales Quantity by Manufacturer (2019-2024)
3.2 Global Neurodegenerative Drugs Revenue by Manufacturer (2019-2024)
3.3 Global Neurodegenerative Drugs Average Price by Manufacturer (2019-2024)
3.4 Market Share Analysis (2023)
3.4.1 Producer Shipments of Neurodegenerative Drugs by Manufacturer Revenue ($MM) and Market Share (%): 2023
3.4.2 Top 3 Neurodegenerative Drugs Manufacturer Market Share in 2023
3.4.2 Top 6 Neurodegenerative Drugs Manufacturer Market Share in 2023
3.5 Neurodegenerative Drugs Market: Overall Company Footprint Analysis
3.5.1 Neurodegenerative Drugs Market: Region Footprint
3.5.2 Neurodegenerative Drugs Market: Company Product Type Footprint
3.5.3 Neurodegenerative Drugs Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global Neurodegenerative Drugs Market Size by Region
4.1.1 Global Neurodegenerative Drugs Sales Quantity by Region (2019-2030)
4.1.2 Global Neurodegenerative Drugs Consumption Value by Region (2019-2030)
4.1.3 Global Neurodegenerative Drugs Average Price by Region (2019-2030)
4.2 North America Neurodegenerative Drugs Consumption Value (2019-2030)
4.3 Europe Neurodegenerative Drugs Consumption Value (2019-2030)
4.4 Asia-Pacific Neurodegenerative Drugs Consumption Value (2019-2030)
4.5 South America Neurodegenerative Drugs Consumption Value (2019-2030)
4.6 Middle East and Africa Neurodegenerative Drugs Consumption Value (2019-2030)
5 MARKET SEGMENT BY TYPE
5.1 Global Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
5.2 Global Neurodegenerative Drugs Consumption Value by Type (2019-2030)
5.3 Global Neurodegenerative Drugs Average Price by Type (2019-2030)
6 MARKET SEGMENT BY APPLICATION
6.1 Global Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
6.2 Global Neurodegenerative Drugs Consumption Value by Application (2019-2030)
6.3 Global Neurodegenerative Drugs Average Price by Application (2019-2030)
7 NORTH AMERICA
7.1 North America Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
7.2 North America Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
7.3 North America Neurodegenerative Drugs Market Size by Country
7.3.1 North America Neurodegenerative Drugs Sales Quantity by Country (2019-2030)
7.3.2 North America Neurodegenerative Drugs Consumption Value by Country (2019-2030)
7.3.3 United States Market Size and Forecast (2019-2030)
7.3.4 Canada Market Size and Forecast (2019-2030)
7.3.5 Mexico Market Size and Forecast (2019-2030)
8 EUROPE
8.1 Europe Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
8.2 Europe Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
8.3 Europe Neurodegenerative Drugs Market Size by Country
8.3.1 Europe Neurodegenerative Drugs Sales Quantity by Country (2019-2030)
8.3.2 Europe Neurodegenerative Drugs Consumption Value by Country (2019-2030)
8.3.3 Germany Market Size and Forecast (2019-2030)
8.3.4 France Market Size and Forecast (2019-2030)
8.3.5 United Kingdom Market Size and Forecast (2019-2030)
8.3.6 Russia Market Size and Forecast (2019-2030)
8.3.7 Italy Market Size and Forecast (2019-2030)
9 ASIA-PACIFIC
9.1 Asia-Pacific Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
9.2 Asia-Pacific Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
9.3 Asia-Pacific Neurodegenerative Drugs Market Size by Region
9.3.1 Asia-Pacific Neurodegenerative Drugs Sales Quantity by Region (2019-2030)
9.3.2 Asia-Pacific Neurodegenerative Drugs Consumption Value by Region (2019-2030)
9.3.3 China Market Size and Forecast (2019-2030)
9.3.4 Japan Market Size and Forecast (2019-2030)
9.3.5 Korea Market Size and Forecast (2019-2030)
9.3.6 India Market Size and Forecast (2019-2030)
9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
9.3.8 Australia Market Size and Forecast (2019-2030)
10 SOUTH AMERICA
10.1 South America Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
10.2 South America Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
10.3 South America Neurodegenerative Drugs Market Size by Country
10.3.1 South America Neurodegenerative Drugs Sales Quantity by Country (2019-2030)
10.3.2 South America Neurodegenerative Drugs Consumption Value by Country (2019-2030)
10.3.3 Brazil Market Size and Forecast (2019-2030)
10.3.4 Argentina Market Size and Forecast (2019-2030)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa Neurodegenerative Drugs Sales Quantity by Type (2019-2030)
11.2 Middle East & Africa Neurodegenerative Drugs Sales Quantity by Application (2019-2030)
11.3 Middle East & Africa Neurodegenerative Drugs Market Size by Country
11.3.1 Middle East & Africa Neurodegenerative Drugs Sales Quantity by Country (2019-2030)
11.3.2 Middle East & Africa Neurodegenerative Drugs Consumption Value by Country (2019-2030)
11.3.3 Turkey Market Size and Forecast (2019-2030)
11.3.4 Egypt Market Size and Forecast (2019-2030)
11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
11.3.6 South Africa Market Size and Forecast (2019-2030)
12 MARKET DYNAMICS
12.1 Neurodegenerative Drugs Market Drivers
12.2 Neurodegenerative Drugs Market Restraints
12.3 Neurodegenerative Drugs Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of Neurodegenerative Drugs and Key Manufacturers
13.2 Manufacturing Costs Percentage of Neurodegenerative Drugs
13.3 Neurodegenerative Drugs Production Process
13.4 Neurodegenerative Drugs Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Neurodegenerative Drugs Typical Distributors
14.3 Neurodegenerative Drugs Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global Neurodegenerative Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Neurodegenerative Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Novartis Basic Information, Manufacturing Base and Competitors
Table 4. Novartis Major Business
Table 5. Novartis Neurodegenerative Drugs Product and Services
Table 6. Novartis Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Novartis Recent Developments/Updates
Table 8. Pfizer Basic Information, Manufacturing Base and Competitors
Table 9. Pfizer Major Business
Table 10. Pfizer Neurodegenerative Drugs Product and Services
Table 11. Pfizer Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Pfizer Recent Developments/Updates
Table 13. Merck Serono Basic Information, Manufacturing Base and Competitors
Table 14. Merck Serono Major Business
Table 15. Merck Serono Neurodegenerative Drugs Product and Services
Table 16. Merck Serono Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Merck Serono Recent Developments/Updates
Table 18. Biogen Idec Basic Information, Manufacturing Base and Competitors
Table 19. Biogen Idec Major Business
Table 20. Biogen Idec Neurodegenerative Drugs Product and Services
Table 21. Biogen Idec Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Biogen Idec Recent Developments/Updates
Table 23. TEVA Basic Information, Manufacturing Base and Competitors
Table 24. TEVA Major Business
Table 25. TEVA Neurodegenerative Drugs Product and Services
Table 26. TEVA Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. TEVA Recent Developments/Updates
Table 28. UCB Basic Information, Manufacturing Base and Competitors
Table 29. UCB Major Business
Table 30. UCB Neurodegenerative Drugs Product and Services
Table 31. UCB Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. UCB Recent Developments/Updates
Table 33. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 34. Boehringer Ingelheim Major Business
Table 35. Boehringer Ingelheim Neurodegenerative Drugs Product and Services
Table 36. Boehringer Ingelheim Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Boehringer Ingelheim Recent Developments/Updates
Table 38. Sanofi Basic Information, Manufacturing Base and Competitors
Table 39. Sanofi Major Business
Table 40. Sanofi Neurodegenerative Drugs Product and Services
Table 41. Sanofi Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Sanofi Recent Developments/Updates
Table 43. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 44. GlaxoSmithKline Major Business
Table 45. GlaxoSmithKline Neurodegenerative Drugs Product and Services
Table 46. GlaxoSmithKline Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. GlaxoSmithKline Recent Developments/Updates
Table 48. Livzon Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 49. Livzon Pharmaceutical Major Business
Table 50. Livzon Pharmaceutical Neurodegenerative Drugs Product and Services
Table 51. Livzon Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Livzon Pharmaceutical Recent Developments/Updates
Table 53. Haisco Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 54. Haisco Pharmaceutical Major Business
Table 55. Haisco Pharmaceutical Neurodegenerative Drugs Product and Services
Table 56. Haisco Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 57. Haisco Pharmaceutical Recent Developments/Updates
Table 58. Jingxin Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 59. Jingxin Pharmaceutical Major Business
Table 60. Jingxin Pharmaceutical Neurodegenerative Drugs Product and Services
Table 61. Jingxin Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 62. Jingxin Pharmaceutical Recent Developments/Updates
Table 63. Dongcheng Biochemicals Basic Information, Manufacturing Base and Competitors
Table 64. Dongcheng Biochemicals Major Business
Table 65. Dongcheng Biochemicals Neurodegenerative Drugs Product and Services
Table 66. Dongcheng Biochemicals Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 67. Dongcheng Biochemicals Recent Developments/Updates
Table 68. Hisun Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 69. Hisun Pharmaceutical Major Business
Table 70. Hisun Pharmaceutical Neurodegenerative Drugs Product and Services
Table 71. Hisun Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 72. Hisun Pharmaceutical Recent Developments/Updates
Table 73. Luye Pharma Basic Information, Manufacturing Base and Competitors
Table 74. Luye Pharma Major Business
Table 75. Luye Pharma Neurodegenerative Drugs Product and Services
Table 76. Luye Pharma Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 77. Luye Pharma Recent Developments/Updates
Table 78. Ark Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 79. Ark Pharmaceutical Major Business
Table 80. Ark Pharmaceutical Neurodegenerative Drugs Product and Services
Table 81. Ark Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 82. Ark Pharmaceutical Recent Developments/Updates
Table 83. Kanghong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 84. Kanghong Pharmaceutical Major Business
Table 85. Kanghong Pharmaceutical Neurodegenerative Drugs Product and Services
Table 86. Kanghong Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 87. Kanghong Pharmaceutical Recent Developments/Updates
Table 88. Huahai Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 89. Huahai Pharmaceutical Major Business
Table 90. Huahai Pharmaceutical Neurodegenerative Drugs Product and Services
Table 91. Huahai Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 92. Huahai Pharmaceutical Recent Developments/Updates
Table 93. BORA PHARMACEUTICALS Basic Information, Manufacturing Base and Competitors
Table 94. BORA PHARMACEUTICALS Major Business
Table 95. BORA PHARMACEUTICALS Neurodegenerative Drugs Product and Services
Table 96. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 97. BORA PHARMACEUTICALS Recent Developments/Updates
Table 98. Global Neurodegenerative Drugs Sales Quantity by Manufacturer (2019-2024) & (MT)
Table 99. Global Neurodegenerative Drugs Revenue by Manufacturer (2019-2024) & (USD Million)
Table 100. Global Neurodegenerative Drugs Average Price by Manufacturer (2019-2024) & (US$/MT)
Table 101. Market Position of Manufacturers in Neurodegenerative Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 102. Head Office and Neurodegenerative Drugs Production Site of Key Manufacturer
Table 103. Neurodegenerative Drugs Market: Company Product Type Footprint
Table 104. Neurodegenerative Drugs Market: Company Product Application Footprint
Table 105. Neurodegenerative Drugs New Market Entrants and Barriers to Market Entry
Table 106. Neurodegenerative Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 107. Global Neurodegenerative Drugs Sales Quantity by Region (2019-2024) & (MT)
Table 108. Global Neurodegenerative Drugs Sales Quantity by Region (2025-2030) & (MT)
Table 109. Global Neurodegenerative Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 110. Global Neurodegenerative Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 111. Global Neurodegenerative Drugs Average Price by Region (2019-2024) & (US$/MT)
Table 112. Global Neurodegenerative Drugs Average Price by Region (2025-2030) & (US$/MT)
Table 113. Global Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)
Table 114. Global Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)
Table 115. Global Neurodegenerative Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 116. Global Neurodegenerative Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 117. Global Neurodegenerative Drugs Average Price by Type (2019-2024) & (US$/MT)
Table 118. Global Neurodegenerative Drugs Average Price by Type (2025-2030) & (US$/MT)
Table 119. Global Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)
Table 120. Global Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)
Table 121. Global Neurodegenerative Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 122. Global Neurodegenerative Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 123. Global Neurodegenerative Drugs Average Price by Application (2019-2024) & (US$/MT)
Table 124. Global Neurodegenerative Drugs Average Price by Application (2025-2030) & (US$/MT)
Table 125. North America Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)
Table 126. North America Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)
Table 127. North America Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)
Table 128. North America Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)
Table 129. North America Neurodegenerative Drugs Sales Quantity by Country (2019-2024) & (MT)
Table 130. North America Neurodegenerative Drugs Sales Quantity by Country (2025-2030) & (MT)
Table 131. North America Neurodegenerative Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 132. North America Neurodegenerative Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 133. Europe Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)
Table 134. Europe Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)
Table 135. Europe Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)
Table 136. Europe Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)
Table 137. Europe Neurodegenerative Drugs Sales Quantity by Country (2019-2024) & (MT)
Table 138. Europe Neurodegenerative Drugs Sales Quantity by Country (2025-2030) & (MT)
Table 139. Europe Neurodegenerative Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 140. Europe Neurodegenerative Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 141. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)
Table 142. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)
Table 143. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)
Table 144. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)
Table 145. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Region (2019-2024) & (MT)
Table 146. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Region (2025-2030) & (MT)
Table 147. Asia-Pacific Neurodegenerative Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 148. Asia-Pacific Neurodegenerative Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 149. South America Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)
Table 150. South America Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)
Table 151. South America Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)
Table 152. South America Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)
Table 153. South America Neurodegenerative Drugs Sales Quantity by Country (2019-2024) & (MT)
Table 154. South America Neurodegenerative Drugs Sales Quantity by Country (2025-2030) & (MT)
Table 155. South America Neurodegenerative Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 156. South America Neurodegenerative Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 157. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)
Table 158. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)
Table 159. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)
Table 160. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)
Table 161. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Region (2019-2024) & (MT)
Table 162. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Region (2025-2030) & (MT)
Table 163. Middle East & Africa Neurodegenerative Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 164. Middle East & Africa Neurodegenerative Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 165. Neurodegenerative Drugs Raw Material
Table 166. Key Manufacturers of Neurodegenerative Drugs Raw Materials
Table 167. Neurodegenerative Drugs Typical Distributors
Table 168. Neurodegenerative Drugs Typical Customers
Table 1. Global Neurodegenerative Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Table 2. Global Neurodegenerative Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Table 3. Novartis Basic Information, Manufacturing Base and Competitors
Table 4. Novartis Major Business
Table 5. Novartis Neurodegenerative Drugs Product and Services
Table 6. Novartis Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 7. Novartis Recent Developments/Updates
Table 8. Pfizer Basic Information, Manufacturing Base and Competitors
Table 9. Pfizer Major Business
Table 10. Pfizer Neurodegenerative Drugs Product and Services
Table 11. Pfizer Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 12. Pfizer Recent Developments/Updates
Table 13. Merck Serono Basic Information, Manufacturing Base and Competitors
Table 14. Merck Serono Major Business
Table 15. Merck Serono Neurodegenerative Drugs Product and Services
Table 16. Merck Serono Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 17. Merck Serono Recent Developments/Updates
Table 18. Biogen Idec Basic Information, Manufacturing Base and Competitors
Table 19. Biogen Idec Major Business
Table 20. Biogen Idec Neurodegenerative Drugs Product and Services
Table 21. Biogen Idec Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 22. Biogen Idec Recent Developments/Updates
Table 23. TEVA Basic Information, Manufacturing Base and Competitors
Table 24. TEVA Major Business
Table 25. TEVA Neurodegenerative Drugs Product and Services
Table 26. TEVA Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 27. TEVA Recent Developments/Updates
Table 28. UCB Basic Information, Manufacturing Base and Competitors
Table 29. UCB Major Business
Table 30. UCB Neurodegenerative Drugs Product and Services
Table 31. UCB Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 32. UCB Recent Developments/Updates
Table 33. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 34. Boehringer Ingelheim Major Business
Table 35. Boehringer Ingelheim Neurodegenerative Drugs Product and Services
Table 36. Boehringer Ingelheim Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 37. Boehringer Ingelheim Recent Developments/Updates
Table 38. Sanofi Basic Information, Manufacturing Base and Competitors
Table 39. Sanofi Major Business
Table 40. Sanofi Neurodegenerative Drugs Product and Services
Table 41. Sanofi Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 42. Sanofi Recent Developments/Updates
Table 43. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 44. GlaxoSmithKline Major Business
Table 45. GlaxoSmithKline Neurodegenerative Drugs Product and Services
Table 46. GlaxoSmithKline Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 47. GlaxoSmithKline Recent Developments/Updates
Table 48. Livzon Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 49. Livzon Pharmaceutical Major Business
Table 50. Livzon Pharmaceutical Neurodegenerative Drugs Product and Services
Table 51. Livzon Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 52. Livzon Pharmaceutical Recent Developments/Updates
Table 53. Haisco Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 54. Haisco Pharmaceutical Major Business
Table 55. Haisco Pharmaceutical Neurodegenerative Drugs Product and Services
Table 56. Haisco Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 57. Haisco Pharmaceutical Recent Developments/Updates
Table 58. Jingxin Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 59. Jingxin Pharmaceutical Major Business
Table 60. Jingxin Pharmaceutical Neurodegenerative Drugs Product and Services
Table 61. Jingxin Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 62. Jingxin Pharmaceutical Recent Developments/Updates
Table 63. Dongcheng Biochemicals Basic Information, Manufacturing Base and Competitors
Table 64. Dongcheng Biochemicals Major Business
Table 65. Dongcheng Biochemicals Neurodegenerative Drugs Product and Services
Table 66. Dongcheng Biochemicals Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 67. Dongcheng Biochemicals Recent Developments/Updates
Table 68. Hisun Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 69. Hisun Pharmaceutical Major Business
Table 70. Hisun Pharmaceutical Neurodegenerative Drugs Product and Services
Table 71. Hisun Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 72. Hisun Pharmaceutical Recent Developments/Updates
Table 73. Luye Pharma Basic Information, Manufacturing Base and Competitors
Table 74. Luye Pharma Major Business
Table 75. Luye Pharma Neurodegenerative Drugs Product and Services
Table 76. Luye Pharma Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 77. Luye Pharma Recent Developments/Updates
Table 78. Ark Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 79. Ark Pharmaceutical Major Business
Table 80. Ark Pharmaceutical Neurodegenerative Drugs Product and Services
Table 81. Ark Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 82. Ark Pharmaceutical Recent Developments/Updates
Table 83. Kanghong Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 84. Kanghong Pharmaceutical Major Business
Table 85. Kanghong Pharmaceutical Neurodegenerative Drugs Product and Services
Table 86. Kanghong Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 87. Kanghong Pharmaceutical Recent Developments/Updates
Table 88. Huahai Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 89. Huahai Pharmaceutical Major Business
Table 90. Huahai Pharmaceutical Neurodegenerative Drugs Product and Services
Table 91. Huahai Pharmaceutical Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 92. Huahai Pharmaceutical Recent Developments/Updates
Table 93. BORA PHARMACEUTICALS Basic Information, Manufacturing Base and Competitors
Table 94. BORA PHARMACEUTICALS Major Business
Table 95. BORA PHARMACEUTICALS Neurodegenerative Drugs Product and Services
Table 96. BORA PHARMACEUTICALS Neurodegenerative Drugs Sales Quantity (MT), Average Price (US$/MT), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
Table 97. BORA PHARMACEUTICALS Recent Developments/Updates
Table 98. Global Neurodegenerative Drugs Sales Quantity by Manufacturer (2019-2024) & (MT)
Table 99. Global Neurodegenerative Drugs Revenue by Manufacturer (2019-2024) & (USD Million)
Table 100. Global Neurodegenerative Drugs Average Price by Manufacturer (2019-2024) & (US$/MT)
Table 101. Market Position of Manufacturers in Neurodegenerative Drugs, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2023
Table 102. Head Office and Neurodegenerative Drugs Production Site of Key Manufacturer
Table 103. Neurodegenerative Drugs Market: Company Product Type Footprint
Table 104. Neurodegenerative Drugs Market: Company Product Application Footprint
Table 105. Neurodegenerative Drugs New Market Entrants and Barriers to Market Entry
Table 106. Neurodegenerative Drugs Mergers, Acquisition, Agreements, and Collaborations
Table 107. Global Neurodegenerative Drugs Sales Quantity by Region (2019-2024) & (MT)
Table 108. Global Neurodegenerative Drugs Sales Quantity by Region (2025-2030) & (MT)
Table 109. Global Neurodegenerative Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 110. Global Neurodegenerative Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 111. Global Neurodegenerative Drugs Average Price by Region (2019-2024) & (US$/MT)
Table 112. Global Neurodegenerative Drugs Average Price by Region (2025-2030) & (US$/MT)
Table 113. Global Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)
Table 114. Global Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)
Table 115. Global Neurodegenerative Drugs Consumption Value by Type (2019-2024) & (USD Million)
Table 116. Global Neurodegenerative Drugs Consumption Value by Type (2025-2030) & (USD Million)
Table 117. Global Neurodegenerative Drugs Average Price by Type (2019-2024) & (US$/MT)
Table 118. Global Neurodegenerative Drugs Average Price by Type (2025-2030) & (US$/MT)
Table 119. Global Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)
Table 120. Global Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)
Table 121. Global Neurodegenerative Drugs Consumption Value by Application (2019-2024) & (USD Million)
Table 122. Global Neurodegenerative Drugs Consumption Value by Application (2025-2030) & (USD Million)
Table 123. Global Neurodegenerative Drugs Average Price by Application (2019-2024) & (US$/MT)
Table 124. Global Neurodegenerative Drugs Average Price by Application (2025-2030) & (US$/MT)
Table 125. North America Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)
Table 126. North America Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)
Table 127. North America Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)
Table 128. North America Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)
Table 129. North America Neurodegenerative Drugs Sales Quantity by Country (2019-2024) & (MT)
Table 130. North America Neurodegenerative Drugs Sales Quantity by Country (2025-2030) & (MT)
Table 131. North America Neurodegenerative Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 132. North America Neurodegenerative Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 133. Europe Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)
Table 134. Europe Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)
Table 135. Europe Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)
Table 136. Europe Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)
Table 137. Europe Neurodegenerative Drugs Sales Quantity by Country (2019-2024) & (MT)
Table 138. Europe Neurodegenerative Drugs Sales Quantity by Country (2025-2030) & (MT)
Table 139. Europe Neurodegenerative Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 140. Europe Neurodegenerative Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 141. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)
Table 142. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)
Table 143. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)
Table 144. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)
Table 145. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Region (2019-2024) & (MT)
Table 146. Asia-Pacific Neurodegenerative Drugs Sales Quantity by Region (2025-2030) & (MT)
Table 147. Asia-Pacific Neurodegenerative Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 148. Asia-Pacific Neurodegenerative Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 149. South America Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)
Table 150. South America Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)
Table 151. South America Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)
Table 152. South America Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)
Table 153. South America Neurodegenerative Drugs Sales Quantity by Country (2019-2024) & (MT)
Table 154. South America Neurodegenerative Drugs Sales Quantity by Country (2025-2030) & (MT)
Table 155. South America Neurodegenerative Drugs Consumption Value by Country (2019-2024) & (USD Million)
Table 156. South America Neurodegenerative Drugs Consumption Value by Country (2025-2030) & (USD Million)
Table 157. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Type (2019-2024) & (MT)
Table 158. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Type (2025-2030) & (MT)
Table 159. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Application (2019-2024) & (MT)
Table 160. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Application (2025-2030) & (MT)
Table 161. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Region (2019-2024) & (MT)
Table 162. Middle East & Africa Neurodegenerative Drugs Sales Quantity by Region (2025-2030) & (MT)
Table 163. Middle East & Africa Neurodegenerative Drugs Consumption Value by Region (2019-2024) & (USD Million)
Table 164. Middle East & Africa Neurodegenerative Drugs Consumption Value by Region (2025-2030) & (USD Million)
Table 165. Neurodegenerative Drugs Raw Material
Table 166. Key Manufacturers of Neurodegenerative Drugs Raw Materials
Table 167. Neurodegenerative Drugs Typical Distributors
Table 168. Neurodegenerative Drugs Typical Customers
LIST OF FIGURES
Figure 1. Neurodegenerative Drugs Picture
Figure 2. Global Neurodegenerative Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Neurodegenerative Drugs Consumption Value Market Share by Type in 2023
Figure 4. NMDA Examples
Figure 5. SSRIs Examples
Figure 6. Dopamine Inhibitors Examples
Figure 7. Global Neurodegenerative Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Neurodegenerative Drugs Consumption Value Market Share by Application in 2023
Figure 9. Parkinson’s Disease Examples
Figure 10. Huntington Disease Examples
Figure 11. Amyotrophic Lateral Sclerosis Examples
Figure 12. Alzheimer’s Disease Examples
Figure 13. Global Neurodegenerative Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global Neurodegenerative Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Neurodegenerative Drugs Sales Quantity (2019-2030) & (MT)
Figure 16. Global Neurodegenerative Drugs Average Price (2019-2030) & (US$/MT)
Figure 17. Global Neurodegenerative Drugs Sales Quantity Market Share by Manufacturer in 2023
Figure 18. Global Neurodegenerative Drugs Consumption Value Market Share by Manufacturer in 2023
Figure 19. Producer Shipments of Neurodegenerative Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 20. Top 3 Neurodegenerative Drugs Manufacturer (Consumption Value) Market Share in 2023
Figure 21. Top 6 Neurodegenerative Drugs Manufacturer (Consumption Value) Market Share in 2023
Figure 22. Global Neurodegenerative Drugs Sales Quantity Market Share by Region (2019-2030)
Figure 23. Global Neurodegenerative Drugs Consumption Value Market Share by Region (2019-2030)
Figure 24. North America Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)
Figure 25. Europe Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)
Figure 26. Asia-Pacific Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)
Figure 27. South America Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)
Figure 28. Middle East & Africa Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)
Figure 29. Global Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 30. Global Neurodegenerative Drugs Consumption Value Market Share by Type (2019-2030)
Figure 31. Global Neurodegenerative Drugs Average Price by Type (2019-2030) & (US$/MT)
Figure 32. Global Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 33. Global Neurodegenerative Drugs Consumption Value Market Share by Application (2019-2030)
Figure 34. Global Neurodegenerative Drugs Average Price by Application (2019-2030) & (US$/MT)
Figure 35. North America Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 36. North America Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 37. North America Neurodegenerative Drugs Sales Quantity Market Share by Country (2019-2030)
Figure 38. North America Neurodegenerative Drugs Consumption Value Market Share by Country (2019-2030)
Figure 39. United States Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Canada Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Mexico Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 42. Europe Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 43. Europe Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 44. Europe Neurodegenerative Drugs Sales Quantity Market Share by Country (2019-2030)
Figure 45. Europe Neurodegenerative Drugs Consumption Value Market Share by Country (2019-2030)
Figure 46. Germany Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. France Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. United Kingdom Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Russia Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Italy Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. Asia-Pacific Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 52. Asia-Pacific Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 53. Asia-Pacific Neurodegenerative Drugs Sales Quantity Market Share by Region (2019-2030)
Figure 54. Asia-Pacific Neurodegenerative Drugs Consumption Value Market Share by Region (2019-2030)
Figure 55. China Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Japan Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Korea Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. India Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Southeast Asia Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. Australia Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. South America Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 62. South America Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 63. South America Neurodegenerative Drugs Sales Quantity Market Share by Country (2019-2030)
Figure 64. South America Neurodegenerative Drugs Consumption Value Market Share by Country (2019-2030)
Figure 65. Brazil Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. Argentina Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 67. Middle East & Africa Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 68. Middle East & Africa Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 69. Middle East & Africa Neurodegenerative Drugs Sales Quantity Market Share by Region (2019-2030)
Figure 70. Middle East & Africa Neurodegenerative Drugs Consumption Value Market Share by Region (2019-2030)
Figure 71. Turkey Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Egypt Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. Saudi Arabia Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. South Africa Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. Neurodegenerative Drugs Market Drivers
Figure 76. Neurodegenerative Drugs Market Restraints
Figure 77. Neurodegenerative Drugs Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Neurodegenerative Drugs in 2023
Figure 80. Manufacturing Process Analysis of Neurodegenerative Drugs
Figure 81. Neurodegenerative Drugs Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
Figure 1. Neurodegenerative Drugs Picture
Figure 2. Global Neurodegenerative Drugs Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
Figure 3. Global Neurodegenerative Drugs Consumption Value Market Share by Type in 2023
Figure 4. NMDA Examples
Figure 5. SSRIs Examples
Figure 6. Dopamine Inhibitors Examples
Figure 7. Global Neurodegenerative Drugs Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
Figure 8. Global Neurodegenerative Drugs Consumption Value Market Share by Application in 2023
Figure 9. Parkinson’s Disease Examples
Figure 10. Huntington Disease Examples
Figure 11. Amyotrophic Lateral Sclerosis Examples
Figure 12. Alzheimer’s Disease Examples
Figure 13. Global Neurodegenerative Drugs Consumption Value, (USD Million): 2019 & 2023 & 2030
Figure 14. Global Neurodegenerative Drugs Consumption Value and Forecast (2019-2030) & (USD Million)
Figure 15. Global Neurodegenerative Drugs Sales Quantity (2019-2030) & (MT)
Figure 16. Global Neurodegenerative Drugs Average Price (2019-2030) & (US$/MT)
Figure 17. Global Neurodegenerative Drugs Sales Quantity Market Share by Manufacturer in 2023
Figure 18. Global Neurodegenerative Drugs Consumption Value Market Share by Manufacturer in 2023
Figure 19. Producer Shipments of Neurodegenerative Drugs by Manufacturer Sales Quantity ($MM) and Market Share (%): 2023
Figure 20. Top 3 Neurodegenerative Drugs Manufacturer (Consumption Value) Market Share in 2023
Figure 21. Top 6 Neurodegenerative Drugs Manufacturer (Consumption Value) Market Share in 2023
Figure 22. Global Neurodegenerative Drugs Sales Quantity Market Share by Region (2019-2030)
Figure 23. Global Neurodegenerative Drugs Consumption Value Market Share by Region (2019-2030)
Figure 24. North America Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)
Figure 25. Europe Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)
Figure 26. Asia-Pacific Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)
Figure 27. South America Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)
Figure 28. Middle East & Africa Neurodegenerative Drugs Consumption Value (2019-2030) & (USD Million)
Figure 29. Global Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 30. Global Neurodegenerative Drugs Consumption Value Market Share by Type (2019-2030)
Figure 31. Global Neurodegenerative Drugs Average Price by Type (2019-2030) & (US$/MT)
Figure 32. Global Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 33. Global Neurodegenerative Drugs Consumption Value Market Share by Application (2019-2030)
Figure 34. Global Neurodegenerative Drugs Average Price by Application (2019-2030) & (US$/MT)
Figure 35. North America Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 36. North America Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 37. North America Neurodegenerative Drugs Sales Quantity Market Share by Country (2019-2030)
Figure 38. North America Neurodegenerative Drugs Consumption Value Market Share by Country (2019-2030)
Figure 39. United States Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 40. Canada Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 41. Mexico Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 42. Europe Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 43. Europe Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 44. Europe Neurodegenerative Drugs Sales Quantity Market Share by Country (2019-2030)
Figure 45. Europe Neurodegenerative Drugs Consumption Value Market Share by Country (2019-2030)
Figure 46. Germany Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 47. France Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 48. United Kingdom Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 49. Russia Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 50. Italy Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 51. Asia-Pacific Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 52. Asia-Pacific Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 53. Asia-Pacific Neurodegenerative Drugs Sales Quantity Market Share by Region (2019-2030)
Figure 54. Asia-Pacific Neurodegenerative Drugs Consumption Value Market Share by Region (2019-2030)
Figure 55. China Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 56. Japan Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 57. Korea Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 58. India Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 59. Southeast Asia Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 60. Australia Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 61. South America Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 62. South America Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 63. South America Neurodegenerative Drugs Sales Quantity Market Share by Country (2019-2030)
Figure 64. South America Neurodegenerative Drugs Consumption Value Market Share by Country (2019-2030)
Figure 65. Brazil Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 66. Argentina Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 67. Middle East & Africa Neurodegenerative Drugs Sales Quantity Market Share by Type (2019-2030)
Figure 68. Middle East & Africa Neurodegenerative Drugs Sales Quantity Market Share by Application (2019-2030)
Figure 69. Middle East & Africa Neurodegenerative Drugs Sales Quantity Market Share by Region (2019-2030)
Figure 70. Middle East & Africa Neurodegenerative Drugs Consumption Value Market Share by Region (2019-2030)
Figure 71. Turkey Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 72. Egypt Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 73. Saudi Arabia Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 74. South Africa Neurodegenerative Drugs Consumption Value and Growth Rate (2019-2030) & (USD Million)
Figure 75. Neurodegenerative Drugs Market Drivers
Figure 76. Neurodegenerative Drugs Market Restraints
Figure 77. Neurodegenerative Drugs Market Trends
Figure 78. Porters Five Forces Analysis
Figure 79. Manufacturing Cost Structure Analysis of Neurodegenerative Drugs in 2023
Figure 80. Manufacturing Process Analysis of Neurodegenerative Drugs
Figure 81. Neurodegenerative Drugs Industrial Chain
Figure 82. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 83. Direct Channel Pros & Cons
Figure 84. Indirect Channel Pros & Cons
Figure 85. Methodology
Figure 86. Research Process and Data Source
